Intratumoral Administration of Interferon-α in Malignant Gliomas

In spite of extensive research and financial efforts, the prognosis in patients with malignant gliomas remains extremely poor. The life expectancy was increased by about 2 months during the last 3 decades, but it still remains one of the shortest in malignancies of any location. Therefore, it is understandable that any new treatment is embraced with great hope and even enthusiasm. The discovery of interferon seems to be a promising step in the treatment of malignant tumors, and favorable results have been reported from Yugoslavia [2], Sweden [1, 7], and Japan [3–6].